522 results on '"Pöttgen, Christoph"'
Search Results
2. Prognostic factors in clear cell sarcoma: an analysis of soft tissue sarcoma in 43 cases
3. Lokalisierte Weichgewebesarkome
4. Strahlentherapie in der geriatrischen Urologie
5. Time interval between the diagnosis of breast cancer and brain metastases impacts prognosis after metastasis surgery
6. Prognostic Factors for Leiomyosarcoma with Isolated Metastases to the Lungs: Impact of Metastasectomy
7. Survivorship program including long‐term toxicities and quality‐of‐life development over 10 years in a randomized trial in operable stage III non‐small‐cell lung cancer (ESPATUE).
8. Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT
9. [68Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas
10. Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment
11. Radiographic markers of breast cancer brain metastases: relation to clinical characteristics and postoperative outcome
12. Strahlentherapie in der geriatrischen Urologie
13. Therapie des metastasierten Mammakarzinoms
14. Correction to: Value of PET imaging for radiation therapy
15. Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
16. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
17. T-VEC in the palliative treatment of Mucosal Melanoma
18. T-VEC Injektion im palliativen Setting von Schleimhautmelanomen
19. Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment—Comparison with Stage III Disease
20. ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy
21. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
22. Measures of infection prevention and incidence of SARS-CoV-2 infections in cancer patients undergoing radiotherapy in Germany, Austria and Switzerland
23. Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition
24. Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma
25. Experimental Examination of Conventional, Semi-Automatic, and Automatic Volumetry Tools for Segmentation of Pulmonary Nodules in a Phantom Study
26. Survivorship Program Including Long-Term Toxicities and Quality-of-Life Development Over Ten Years within a Randomized Phase-III Trial in Operable Stage III Non-Small-Cell Lung Cancer (ESPATUE)
27. Impact of Modern Low Dose Involved Site Radiation Therapy on Normal Tissue Toxicity in Cervicothoracic Non-Hodgkin Lymphomas: A Biophysical Study
28. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial
29. Adaptation Time as a Determinant of the Dosimetric Effectiveness of Online Adaptive Radiotherapy for Bladder Cancer
30. CTNI-65. INVESTIGATING SAFETY AND EFFICACY OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA - FIRST RESULTS OF THE PRICOTTF PHASE I/II TRIAL
31. Fractionation versus Adaptation for Compensation of Target Volume Changes during Online Adaptive Radiotherapy for Bladder Cancer: Answers from a Prospective Registry
32. Giant middle mediastinal lesions: when tumor size correlates with mesenchymal origin—a retrospective single-center analysis
33. Safety and efficacy of tumor treating fields (TTFields) prior and concomitant to radiotherapy in patients with newly diagnosed glioblastoma: Results from PriCoTTF.
34. Radiation Therapy in Non-small-Cell Lung Cancer
35. Experimental Examination of Conventional, Semi-Automatic, and Automatic Volumetry Tools for Segmentation of Pulmonary Nodules in a Phantom Study.
36. Location of Recurrences after Trimodality Treatment for Glioblastoma with Respect to the Delivered Radiation Dose Distribution and Its Influence on Prognosis
37. Comparison of Online-Onboard Adaptive Intensity-Modulated Radiation Therapy or Volumetric-Modulated Arc Radiotherapy With Image-Guided Radiotherapy for Patients With Gynecologic Tumors in Dependence on Fractionation and the Planning Target Volume Margin
38. Correction: ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy
39. Machine-learning-based prediction of the effectiveness of the delivered dose by exhale-gated radiotherapy for locally advanced lung cancer: The additional value of geometric over dosimetric parameters alone
40. Machine-learning-based prediction of the effectiveness of the delivered dose by exhale-gated radiotherapy for locally advanced lung cancer: The additional value of geometric over dosimetric parameters alone
41. Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers: Secondary results of two European randomized phase III trials (ARO 95-06, SAKK 10/94)
42. CTNI-29. INVESTIGATING SAFETY AND EFFICACY OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA - FIRST RESULTS OF THE PRICOTTF PHASE I/II TRIAL
43. Feasibility, Method and Early Outcome of Image-Guided Volumetric Modulated Arc Radiosurgery Followed by Resection for AJCC Stage IIA–IIIB High-Risk Large Intraocular Melanoma
44. Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors
45. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial
46. Combined immunotherapy with ipilimumab plus nivolumab in metastatic PD‐1/PD‐L1‐refractory Merkel cell carcinoma—a case report.
47. Prediction of Short and Long Survival after Surgery for Breast Cancer Brain Metastases
48. Auf maschinellem Lernen basierende Vorhersage der uniformen Equivalentdosis im CTV bei der in exhale gagateten VMAT oder IMRT beim lokal fortgeschrittenem NSCLC : zusätzlicher Wert von geometrischen/anatomischen gegenüber rein dosimetrischen Parametern?
49. Robuste und lang-andauernde Wirksamkeit der Durvalumab-Konsolidierung bei NSCLC im Stadium III nach Induktionschemotherapie und definitiver Radiochemotherapie : Fokus auf Behandlungsauswahl und prognostische Faktoren
50. A Investigating safety and efficacy of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma : The PriCoTTF phase I/II trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.